Background
Myocardial T1 and extracellular volume (ECV) estimates have applications in a range of myocardial diseases. Factors responsible for systematic inaccuracies in T1 mapping are beginning to be known 1-4 but little is known about its delivery at 'health-care system' scale and there is no global quality assurance (QA) system. Agarose phantoms are common in MRI and nickel ions preferred for lower temperature sensitivity 5 . This program aims to 1 Create a partnership to design 1.5/3T phantoms for any manufacturer/sequence reflecting myocardial/blood T1 pre/post-contrast 2 Test and mass produce phantoms to regulatory standards 3 Distribute globally 4 Analyse serial scans to understand T1 mapping at scale 5 Publish recipes 6 Explore delivery of a 'T1/ECV Standard' via local calibration
We report results of steps 1-3.
Methods
A design collaboration was created (clinicians/physicists/ regulatory bodies/SME). After identifying critical design factors ( Fig 1A) and discarding models with excessive B 0 /B 1 distortion, the layout in Fig 1B was adopted. 9 tubes with differently doped agarose were embedded in a gel matrix and high-density polyethylene (HDPE) macrobeads added for B 1 homogeneity. Tube diameter >20 mm was needed for regions of interest to exclude Gibbs artifacts. B 0 /B 1 homogeneity was mapped to evaluate distortion. We hypothesised that dilution of dielectric permittivity by HDPE beads would reduce B 1 inhomogeneity. This design was compared to ones using sodium chloride (NaCl) for increased conductivity, sucrose for reduced permittivity or poly methyl-methacrylate (PMMA) microbeads. Tubes with T1 = 250-1900 ms and T2 = 45-250 ms were reproducibly manufactured and separate ranges adopted for 1.5/3T (Fig 1C) . 10 Prototypes were fabricated (5 each for 1.5/3T) for gold standard measurements: T1 by inversion-recovery spin echo(IRSE, 8 inversion times, 25>3200 ms); T2 by SE(8 echo times, 10>640 ms). Prototypes were then distributed to 9 experienced/regulatory centres for further testing.
Results
T1 maps were free from off-resonance artifacts (Fig 1D) . The bottle geometry, coaxial with z and imaged transversely, showed < ± 0.3 ppm B 0 uniformity (Fig 2A) . HDPE beads flattened the B 1 field at 3T (Fig 2B) especially compared to NaCl, sucrose and PMMA beads. T1 increased with temperature (0.19-1.54% change/°C) while T2 decreased(-0.93-1.45% change/°C). Comparison of gold standard values (Fig 2C,D) between prototypes confirmed reproducible manufacturing(coefficients of variation T1 0.97/1.35%, T2 1.25/2.73% for 1.5T/3T). Recipes were submitted for regulatory approval and manufacture will be complete by Sep'15. 
Conclusions
We created a collaboration to develop CE/FDA-approved phantoms for QA of T1 and ECV protocols. 70 revised phantoms with a multi-vendor user manual are now being distributed to centres worldwide for a 1-year academic exploration of T1 mapping sequences, platform performance and stability. Figure 2 2A B 0 field homogeneity across the 9 phantom compartments as a measure of off resonance in Hz at 3T. 2B Diagonal profile of the B 1 field as per green line in 1D comparing relative flip angles on Siemens 3T system. Variance of B 1 was smallest across the 9 compartments with CoV 1.54% for HDPE beads measuring 2 to 4.8 mm. Highly monosized microbeads measured 6µm and were composed of crosslinked PMMA polymer. Neither microbeads, sucrose nor NaCl efficiently flattened the B 1 field. 2C and 2D Variation in the mean T1 and T2 gold standard values and corresponding standard deviation shown as whiskers for all the D model prototype phantoms at 1.5 and 3T.
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